Skip to content
Screener

Discontinued — last reported Q4 '21

Operating margin at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
26.5%+2.8pp
Amgen logo
AmgenAMGN
30%+6.5pp
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
24.7%-2.3pp
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-1,050.2%+266pp
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-5,266.4%-9,520pp
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
-83.9%

Other financials

Income statement

See full
Revenue-
Operating income-$57.3M+24.5%
Net income-$53.7M+23.3%
EPS (diluted)-$0.69+24.2%

Balance sheet

See full
Cash & equivalents$78.6M+8.0%
Total debt$2.1M+36.3%
Total equity$408.7M-30.8%
Total assets$363.8M-30.1%

Cash flow

See full
Operating cash flow-$38.2M+33.7%
CapEx$11.0K
Free cash flow-$38.1M-4.1%

Valuation

See full
Market cap$1.16B+148%
Enterprise value$1.08B+174%

Profitability

See full
Net margin-346.1%

Returns & leverage

See full
Return on equity-44%+26.2pp
Debt / equity0.0×
Current ratio8.4×-1.4×

Where this comes from

Calculated from Cullinan Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The source filing: Cullinan Therapeutics, Inc.’s 10-K, filed March 9, 2023. Open the filing →

Filed
Mar 9, 2023
Fiscal year
FY2022
Accession
0000950170-23-006839

FAQ

What is Cullinan Therapeutics, Inc.'s operating margin?
Cullinan Therapeutics, Inc. (CGEM) reported operating margin of -358.7% in Q4 2021.
What does operating margin mean?
Operating income as a percentage of revenue (trailing twelve months). Captures profitability from core operations after both cost of revenue and operating expenses, but before interest and taxes.

Ask your AI about Cullinan Therapeutics, Inc.'s operating margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude